Tags

Type your tag names separated by a space and hit enter

Pharmacokinetics and dialysability of isradipine in chronic haemodialysis patients.
Eur J Clin Pharmacol. 1992; 42(2):231-3.EJ

Abstract

The pharmacokinetics of isradipine, a calcium-channel blocker, have been studied in eight patients on chronic haemodialysis. A single oral dose of 5 mg was administered on both a non-haemodialysis and a haemodialysis day and the plasma concentrations of isradipine were analyzed. The mean cmax, tmax, AUC, and t1/2 in plasma on the non-haemodialysis day were 5.2 ng.ml-1, 1.4 h, 23.8 ng.h.ml-1, and 3.1 h, respectively. The dialysis clearance of isradipine was negligible (5.0 ml.min-1). The t1/2 values during haemodialysis were not significantly different from those observed during the same period post dose on the non-haemodialysis day. The study demonstrates that supplemental doses of isradipine are not necessary in these patients since isradipine is not significantly removed by haemodialysis.

Authors+Show Affiliations

Dipartimento di Medicina Interna, Ospedale San Giovanni, Bellinzona, Switzerland.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

1535593

Citation

Schönholzer, K, and C Marone. "Pharmacokinetics and Dialysability of Isradipine in Chronic Haemodialysis Patients." European Journal of Clinical Pharmacology, vol. 42, no. 2, 1992, pp. 231-3.
Schönholzer K, Marone C. Pharmacokinetics and dialysability of isradipine in chronic haemodialysis patients. Eur J Clin Pharmacol. 1992;42(2):231-3.
Schönholzer, K., & Marone, C. (1992). Pharmacokinetics and dialysability of isradipine in chronic haemodialysis patients. European Journal of Clinical Pharmacology, 42(2), 231-3.
Schönholzer K, Marone C. Pharmacokinetics and Dialysability of Isradipine in Chronic Haemodialysis Patients. Eur J Clin Pharmacol. 1992;42(2):231-3. PubMed PMID: 1535593.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacokinetics and dialysability of isradipine in chronic haemodialysis patients. AU - Schönholzer,K, AU - Marone,C, PY - 1992/1/1/pubmed PY - 1992/1/1/medline PY - 1992/1/1/entrez SP - 231 EP - 3 JF - European journal of clinical pharmacology JO - Eur J Clin Pharmacol VL - 42 IS - 2 N2 - The pharmacokinetics of isradipine, a calcium-channel blocker, have been studied in eight patients on chronic haemodialysis. A single oral dose of 5 mg was administered on both a non-haemodialysis and a haemodialysis day and the plasma concentrations of isradipine were analyzed. The mean cmax, tmax, AUC, and t1/2 in plasma on the non-haemodialysis day were 5.2 ng.ml-1, 1.4 h, 23.8 ng.h.ml-1, and 3.1 h, respectively. The dialysis clearance of isradipine was negligible (5.0 ml.min-1). The t1/2 values during haemodialysis were not significantly different from those observed during the same period post dose on the non-haemodialysis day. The study demonstrates that supplemental doses of isradipine are not necessary in these patients since isradipine is not significantly removed by haemodialysis. SN - 0031-6970 UR - https://www.unboundmedicine.com/medline/citation/1535593/Pharmacokinetics_and_dialysability_of_isradipine_in_chronic_haemodialysis_patients_ L2 - https://dx.doi.org/10.1007/BF00278492 DB - PRIME DP - Unbound Medicine ER -